Compare Amphastar Pharmaceuticals Inc (AMPH) vs SiTime Corporation (SITM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while SiTime Corporation trades at $619.94 (market cap $18.83B). The key difference: SiTime Corporation is far larger — about 22.8× Amphastar Pharmaceuticals Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | SITM | |
|---|---|---|
Market Cap | $826.08M | $18.83B |
Sector | Health | Technology |
52-Week High | $30.81 | $901.60 |
52-Week Low | $16.87 | $190.16 |
Enterprise Value | $1.22B | $18.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
SITM trades at $628.94, down 2.96% on the day, with a bearish technical signal from moving averages. The company shows strong revenue growth and consistent earnings beats, with Q1 2026 EPS of $1.44 surpassing estimates. Recent acquisition of Renesas' timing business and raised AI-driven growth guidance highlight strategic expansion. However, negative net income margins and high P/S ratio of 42.42 indicate valuation concerns amid profitability challenges.
Outlook remains positive with 100% analyst buy ratings and a $743.75 consensus target, suggesting 18% upside. Key risks include sustained unprofitability, integration execution from acquisitions, and market volatility. The stock's trajectory hinges on achieving projected 2026 profitability improvements and capitalizing on AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
